These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 19383034)

  • 1. Exenatide: a review from pharmacology to clinical practice.
    Gentilella R; Bianchi C; Rossi A; Rotella CM
    Diabetes Obes Metab; 2009 Jun; 11(6):544-56. PubMed ID: 19383034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
    Nauck MA; Duran S; Kim D; Johns D; Northrup J; Festa A; Brodows R; Trautmann M
    Diabetologia; 2007 Feb; 50(2):259-67. PubMed ID: 17160407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
    Iltz JL; Baker DE; Setter SM; Keith Campbell R
    Clin Ther; 2006 May; 28(5):652-65. PubMed ID: 16861088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
    Schnabel CA; Wintle M; Kolterman O
    Vasc Health Risk Manag; 2006; 2(1):69-77. PubMed ID: 17319471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide: new drug. Type 2 diabetes for some overweight patients.
    Prescrire Int; 2007 Dec; 16(92):228-31. PubMed ID: 18087791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.
    Davies MJ; Donnelly R; Barnett AH; Jones S; Nicolay C; Kilcoyne A
    Diabetes Obes Metab; 2009 Dec; 11(12):1153-62. PubMed ID: 19930005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin.
    Riddle MC; Henry RR; Poon TH; Zhang B; Mac SM; Holcombe JH; Kim DD; Maggs DG
    Diabetes Metab Res Rev; 2006; 22(6):483-91. PubMed ID: 16634116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
    Karagianni P; Polyzos SA; Kartali N; Zografou I; Sambanis C
    Adv Med Sci; 2013; 58(1):38-43. PubMed ID: 23640946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide versus glibenclamide in patients with diabetes.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of exenatide in Asian Indians in a clinical care setting.
    Sudhakaran C; Fathima M; Anjana RM; Unnikrishnan RI; Mohan V
    Diabetes Technol Ther; 2010 Aug; 12(8):613-8. PubMed ID: 20615102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.